Table q1_q4_2019_prescription_drugs_wac

Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like F*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000063	Ferring Pharmaceuticals	03/31/2019	55566280001	Cervidil 10MG VAGINAL INSERT (dinoprostone, 10mg)	01/08/2019	35.62	410.59	None	Single Source Drug	None	1	None	1	None	1	10/01/2015	Allergan PLC	None	1	None	306.27	None	1995	140.00	None	None
Rx0000063	Ferring Pharmaceuticals	03/31/2019	55566650003	Endometrin 100 MG SUPPOSITORY (progesteron vaginal inserts 100 mg)	01/08/2019	14.14	249.70	11/17/2019	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000063	Ferring Pharmaceuticals	06/30/2019	55566750102	MENOPUR (menotropins for injection)	04/19/2019	55.95	988.25	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Note: The package WAC price represents 5 Vials of Menopur.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323036061	Calcium Gluconate 10g 100mL Plastic Vial	06/07/2019	300.00	900.00	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323036059	Calcium Gluconate 5g 50mL SDV Plastic	06/07/2019	187.50	562.50	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	63323001095	Gentamicin 800mg 20mL MDV Premier Pro Rx (package size 25 vials)	08/30/2019	102.00	556.75	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	63323045909	Heparin Sodium 40,000USP 4mL MDV	04/26/2019	67.50	248.75	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range).
Rx0000129	Fresenius Kabi USA LLC	12/31/2019	63323026255	Heparin Sodium Inj NovaPlus Liquid 5000 usp 3mL	10/01/2019	16.25	50.00	None	Innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	76045010810	Simplist® Heparin Sodium Injection, USP 5,000 Units 1 mL. (package size: 24 injections)	07/17/2019	32.88	92.40	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	01/07/2016	Becton Dickinson and Company	None	1	This product was acquired when we purchased BDRx, Inc. The terms of this deal were not made public. The agreement was in the form of a stock deal, not an asset deal, so there is no way to determine the cost of this molecule individually.	59.52	None	2016	59.52	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (4) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes. (5) This product was not launched by prior manufacturer. It was first introduced to the market by Fresenius Kabi 11 months after the acquisition.
Rx0000129	Fresenius Kabi USA LLC	06/30/2019	76045010710	Simplist® Ketorolac Tromethamine Injection, USP 15 mg 1 mL	04/26/2019	23.04	80.64	04/23/2032	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) The patent for this product applies to the primary container (syringe), not the molecule.
Rx0000129	Fresenius Kabi USA LLC	09/30/2019	63323030502	Tobramycin 20mg 2mL Pediatric MDV (package size: 25 vials)	08/30/2019	36.50	132.00	None	Non-innovator Multiple Source Drug	None	1	None	1	No	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Fresenius Kabi USA (“Fresenius Kabi”) believes is otherwise in the public domain or publicly available. Where possible, Fresenius Kabi has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Column F, Fresenius Kabi did not provide a patent expiration date for products that have lost patent exclusivity. (3) For Columns N-U, Fresenius Kabi has not provided a response for "drug products" (as defined in the regulations) that were not acquired in their finished form from an unrelated company in the previous 5 years. (4) Fresenius Kabi USA's product portfolio, including this product, consists primarily of sterile injectable products administered during a patient's inpatient hospital stay. Such hospital stays are subject to variability depending upon a particular patient's needs. The dosing requirements as set forth in the prescribing information for these products are given as a range, based in large part on the number of days of the patient's admission. As such, Fresenius Kabi has based its calculations for purposes of this submission on the recommended dosage for the average length of stay within range present in the product's prescribing information. For example, if a product's prescribing information requires the administration of 1 vial of drug product per day over the course of a 3 to 5 day admission, Fresenius Kabi has based the calculation on 1 vial administered during a 4-day patient admission (an average of the 3-5 day range). (5) Please note that although the WAC pricing provided in this submission is at that pack level for this reporting purpose, none of these products are administered at a pack level for course of therapy purposes.
Rx0000100	Fresenius Medical Care	03/31/2019	49230064331	PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE	01/01/2019	7.04	147.86	02/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	THIS WAC INCREASE IS NOT NECCESSITATED BY A CHANGE OR IMPROVEMENT IN THE PRESCRIPTION DRUG	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care did not acquire Phoslyra in the prior five year period.
Rx0000100	Fresenius Medical Care	12/31/2019	49230064331	PHOSLYRA 667MG/5ML ORAL SOLUTION 473ML BOTTLE	10/01/2019	6.89	154.75	02/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care did not acquire Phoslyra in the prior five year period.
Rx0000100	Fresenius Medical Care	03/31/2019	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	01/01/2019	56.92	1195.31	01/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	THIS WAC INCREASE IS NOT NECCESSITATED BY A CHANGE OR IMPROVEMENT IN THE PRESCRIPTION DRUG	None	01/10/2014	Vifor Fresenius Medical Care Renal Pharma Ltd.	None	1	n/a	855.00	None	2014	855.00	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius is the authorized distributor for Velphoro.
Rx0000100	Fresenius Medical Care	12/31/2019	49230064551	VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE	10/01/2019	55.70	1251.01	01/23/2030	Single Source Drug	None	1	The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code § 6250 et seq. (“PRA”) as the material contains and constitutes FUSA’s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information. Fresenius Medical Care is the authorized distributor for Velphoro. Fresenius Medical Care did not acquire Velphoro in the prior five year period.